DAX23.590 -0,2%Est505.749 -0,8%MSCI World4.343 -0,1%Top 10 Crypto9,1600 -1,7%Nas22.312 -1,8%Bitcoin62.041 +1,3%Euro1,1504 -0,1%Öl100,6 -1,2%Gold5.110 +0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Deutsche Bank 514000 Lufthansa 823212 BioNTech (ADRs) A2PSR2 NVIDIA 918422 SAP 716460 Siemens Energy ENER6Y DroneShield A2DMAA Allianz 840400 Volkswagen (VW) vz. 766403 Bayer BAY001 RENK RENK73 TUI TUAG50 BASF BASF11 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich knapp tiefer -- US-Börsen rot -- RWE besser als befürchtet -- BMW: Schwache Zahlen -- PayPay mit starkem IPO -- Hims & Hers, Ballard Power, DroneShield, Ölpreise, Rüstungsaktien im Fokus
Top News
iPhone 17 Pro im Vodafone Business Prime L Tarif jetzt mit exklusivem Vorteil sichern iPhone 17 Pro im Vodafone Business Prime L Tarif jetzt mit exklusivem Vorteil sichern
ETF-Investment mit saisonalen Strategien - Das steckt dahinter ETF-Investment mit saisonalen Strategien - Das steckt dahinter
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Nanobiotix SA Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
27,45 EUR -1,25 EUR -4,36 %
BMN
27,45 EUR -1,55 EUR -5,34 %
PAR
finanzen.net zero
Nanobiotix SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,40 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J7EB

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0011341205

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNNBXF

Nanobiotix SA Aktien News

DatumMeistgelesen
BenzingaLooking Into Nanobiotix SA's Recent Short Interest
MotleyFoolBiotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
BenzingaNanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer
Wer­bungNanobiotix SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BenzingaMelanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
BenzingaRadian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
GlobeNewswireNanobiotix Provides First Quarter 2025 Operational and Financial Update
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
GlobeNewswireNanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
GlobeNewswireNanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswireNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
GlobeNewswireNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
GlobeNewswireNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
BenzingaCancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
GlobeNewswireNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNanobiotix to Participate in Multiple Investor Conferences in February and March 2025
GlobeNewswireNANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
GlobeNewswireNANOBIOTIX to Participate in Multiple Investor Conferences in November
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
GlobeNewswireNANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
GlobeNewswireNanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
GlobeNewswireVoting Rights and Shares Capital of the Company
GlobeNewswireNanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Ther
GlobeNewswireNANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

Nanobiotix SA News

Nanobiotix SA News: auf dieser Seite finden Sie alle Nanobiotix SA News und Nachrichten zur Nanobiotix SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Nanobiotix SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Nanobiotix SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.